Market requirements · GB
United Kingdom
The United Kingdom prohibits the sale or supply of any unauthorised medicinal product outright under the Human Medicines Regulations 2012, and layers the Misuse of Drugs Act 1971 on top for named peptide hormones, which no EU market does in the same way. Classification turns on presentation and pharmacological function rather than on the description a seller applies. Since 1 January 2021 a shipment from the EU into Great Britain is an import, not an intra-market movement, which adds a licensing layer no EU buyer faces.
Buyers in this market search for: peptide supplier uk, wholesale peptides uk, best peptide supplier uk.
| Tell us the compounds you need for United Kingdom. | Ask about United Kingdom |
The regime
How compounds are classified in United Kingdom
| Governing law | The Human Medicines Regulations 2012 (SI 2012/1916) are the primary instrument. Regulation 46 provides that a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product, and extends that prohibition to possession where the holder has reasonable cause to believe the product is intended for supply. Regulation 18 requires a wholesale dealer's licence to distribute a medicinal product by way of wholesale dealing or to import one into Great Britain. Separately, the Misuse of Drugs Act 1971 (Modification) Order 1996 placed somatropin, somatotropin, somatrem and chorionic gonadotrophin in Class C. |
|---|---|
| What determines classification | MHRA Guidance Note 8 sets out a two-limb test. The first limb is presentational and weighs all claims made for a product, explicit and implicit, including websites, testimonials, linked publications and social media, alongside product names, labelling and packaging. A product may be determined a medicinal product solely under that first limb. The second limb is functional. The MHRA classifies case by case, and a business can request a formal opinion through the Medicines Borderline Advice Form. |
| Post-Brexit import position | From 1 January 2021 goods moving from the EU into Great Britain are imports. MHRA guidance confirms that a Wholesale Dealer's Licence WDA(H) is required to import from a country on the approved country for import list, that a Manufacturer's Specials Licence is required where the source is not on that list, and that a Great Britain business may need a Responsible Person for Import. The Border Target Operating Model applies in part: its safety and security controls reach all imports, while its sanitary and phytosanitary limb is scoped to animal and plant products. Northern Ireland differs under the Windsor Framework, where from 1 January 2025 the MHRA is the sole approving authority and packs must be marked UK only. |
| Prescription-only compounds | The MHRA publishes no consolidated list of prescription-only substances. Legal status is set product by product in each marketing authorisation under regulation 62, and regulation 214 then bars supply except against a prescription. Against that, somatropin and chorionic gonadotrophin are Class C controlled drugs in Schedule 4 Part II, confirmed in the Home Office controlled drugs list. Menotrophin does not appear on that list and its status is not established from any published source. No United Kingdom position was located for tesamorelin or bremelanotide, which means the operative bar for them is regulation 46 rather than prescription control. |
| Enforcement posture | Active and peptide-specific. In February 2026 the MHRA Criminal Enforcement Unit raided premises in Lincolnshire and Nottinghamshire and seized almost 2,000 doses of unauthorised weight loss medicines awaiting dispatch, alongside manufacturing equipment and packaging, from sites reported to involve retatrutide, tirzepatide and peptide products. That followed the dismantling of a Northampton facility in October 2025. Under Operation Pangea, run with Interpol between December 2024 and May 2025, the unit reported seizing 7.7 million doses of illicit medicines and removing 367 websites and accounts. |
| Already supplying United Kingdom? Send the compounds and volumes you buy today and we will quote against them. | Send your list |
Your obligations
What a buyer in United Kingdom needs settled
- Obtain a Wholesale Dealer's Licence WDA(H) from the MHRA before importing any peptide into Great Britain for onward wholesale supply, and appoint a Responsible Person for Import if your business is established in Great Britain.
- Confirm in writing that your supplier holds a wholesale distribution or manufacturer's authorisation in its own state, because regulation 44(2) forbids a licence holder from obtaining supplies from anyone else.
- Apply to the Home Office for a separate per-consignment import licence for anything containing somatropin or chorionic gonadotrophin, and endorse the shipped quantity on the NDS portal after shipment.
- Register for a GB EORI number before your first shipment, and settle import VAT either at the border or through postponed VAT accounting.
- Keep transaction, storage and onward supply records to the good distribution practice standard that regulation 43(1) imposes on every licence holder.
- Audit every listing, product name, page and testimonial against the first limb of Guidance Note 8 before publication, since presentation alone can make a product medicinal.
We will ask about this at enquiry. We check the authorisations your activity requires before quoting, and we confirm the position per compound rather than for the market as a whole.
Sources
Check this yourself
Every position above traces to a dated public document. The authority, the document, the date and the link are below.
| Authority and document | Date | Link |
|---|---|---|
| UK Parliament The Human Medicines Regulations 2012, SI 2012/1916 | 2012, as amended | www.legislation.gov.uk/uksi/2012/1916/contents |
| UK Parliament Human Medicines Regulations 2012, regulation 46, requirement for authorisation | 2012, as amended | www.legislation.gov.uk/uksi/2012/1916/regulation/46 |
| UK Parliament The Misuse of Drugs Act 1971 (Modification) Order 1996, SI 1996/1300 | 1996 | www.legislation.gov.uk/uksi/1996/1300/made |
| MHRA Guidance Note 8, a guide to what is a medicinal product | 2025 | www.gov.uk/guidance/borderline-products-how-to-tell-if-you... |
| MHRA and DHSC Import a human medicine | 2025 | www.gov.uk/guidance/import-a-human-medicine |
| Home Office Controlled drugs, import and export licences | 2026 | www.gov.uk/guidance/controlled-drugs-import-and-export-lic... |
| MHRA MHRA disrupts second manufacturing facility suspected of making illegal weight loss medicines | 2026 | www.gov.uk/government/news/mhra-disrupts-second-manufactur... |
Links go to the issuing body wherever one exists. Positions change. If you are relying on any of this, check the source rather than this page.
Market brief
Take the United Kingdom brief as a PDF
The regime, the buyer obligations and all 7 sources, dated and linked, in one document you can forward.
Nearby
Britain and Ireland and nearby markets
Buyers supplying one of these usually supply the others. The requirements are not the same.
| Code | Market | Sources | |
|---|---|---|---|
| IE | Ireland | 2 sources | The HPRA detained 763,027 dosage units of falsified or unauthorised medicines ... |
| DE | Germany | 2 sources | Germany applies the Arzneimittelgesetz alongside anti-doping legislation, and ... |
| NL | Netherlands | 3 sources | The IGJ and the NVWA assess offerings jointly and have stated their position o... |
Scope
How to use this page
A summary of the published regulatory position in United Kingdom as at 2026-08-20, written for procurement teams deciding how to source. Every source is dated and linked so it can be checked at origin.
It is not legal advice. Full terms of supply, including where responsibility sits, are set out in our terms of supply.
Questions
Supplying into United Kingdom
Do you supply into United Kingdom?
We supply businesses that hold the authorisations their activity requires. Whether a specific compound can be supplied into United Kingdom depends on that compound and on your authorisations, and we confirm it per compound at the enquiry stage.
Who carries the compliance obligation?
The importer of record and the party placing the product on the market, which is the buyer. We supply the batch documentation that supports your file. We cannot hold your authorisations for you.
How current is this page?
It was reviewed on 2026-08-20 and is scheduled for review again on 2026-11-18. Every source is dated and linked, so you can check the original.
We already supply into United Kingdom. What changes if we source from you?
The batch documentation. You receive a Certificate of Analysis per batch, which can be issued under your own brand. The import and market-placing responsibilities stay where they are.
Is this legal advice?
No. It is a summary of the regulatory positions those authorities have published, as at the review date above. Take advice in your own market before you rely on it.
Enquire about supply into United Kingdom
Tell us the compounds and your authorisations. We confirm per compound before anything ships.